PALISADE BIO Files 8-K for Regulation FD Disclosure

Ticker: PALI · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1357459

Palisade Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyPalisade Bio, Inc. (PALI)
Form Type8-K
Filed DateJan 29, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, compliance, routine-filing

TL;DR

**PALI filed a routine 8-K for Regulation FD disclosure, no major news.**

AI Summary

PALISADE BIO, INC. filed an 8-K on January 29, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This filing, under the ticker PALI on the Nasdaq Capital Market, indicates that the company is providing current information to the public, which is a routine compliance matter. For investors, this matters because it signals the company is adhering to its disclosure obligations, maintaining transparency, and potentially setting the stage for future announcements, though this specific filing doesn't contain new material financial events.

Why It Matters

This filing demonstrates PALISADE BIO's commitment to regulatory compliance and transparency, which is crucial for maintaining investor confidence and market integrity.

Risk Assessment

Risk Level: low — This 8-K is a routine compliance filing and does not disclose any new material risks or events.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material news, and would continue to monitor for future substantive disclosures or operational updates from PALISADE BIO.

Key Numbers

  • January 29, 2024 — Date of Report (The earliest event reported in this 8-K filing.)
  • 001-33672 — Commission File Number (PALISADE BIO's unique identifier with the SEC.)
  • $0.01 — Par value per share (The stated par value of PALISADE BIO's Common Stock.)

Key Players & Entities

  • PALISADE BIO, INC. (company) — the registrant filing the 8-K
  • Nasdaq Capital Market (company) — the exchange where PALISADE BIO's common stock is registered
  • PALI (company) — the trading symbol for PALISADE BIO's common stock
  • January 29, 2024 (date) — the date of the earliest event reported in the 8-K
  • 001-33672 (dollar_amount) — the Commission File Number for PALISADE BIO
  • 52-2007292 (dollar_amount) — the IRS Employer Identification Number for PALISADE BIO
  • $0.01 (dollar_amount) — the par value per share of PALISADE BIO's common stock

Forward-Looking Statements

  • PALISADE BIO will continue to file routine compliance documents. (PALISADE BIO, INC.) — high confidence, target: 2024-12-31
  • No significant stock price movement will result directly from this specific 8-K. (PALI) — high confidence, target: 2024-02-05

FAQ

What is the purpose of this 8-K filing by PALISADE BIO, INC.?

This 8-K filing by PALISADE BIO, INC. is primarily for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as indicated in the 'ITEM INFORMATION' section of the filing.

What is the trading symbol and exchange for PALISADE BIO, INC. common stock?

The trading symbol for PALISADE BIO, INC. common stock is 'PALI' and it is registered on the 'Nasdaq Capital Market', as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the date of the earliest event reported in this 8-K?

The 'Date of Report (Date of earliest event reported)' is 'January 29, 2024', according to the filing.

What is the state of incorporation for PALISADE BIO, INC.?

PALISADE BIO, INC. is incorporated in 'Delaware', as specified in the filing under 'State or Other Jurisdiction of Incorporation'.

What is the business address and phone number of PALISADE BIO, INC.?

The business address is '7750 El Camino Real Suite 2A, Carlsbad, California 92009' and the telephone number is '(858) 704-4900', as listed in the filing.

Filing Stats: 1,057 words · 4 min read · ~4 pages · Grade level 14.3 · Accepted 2024-01-29 08:30:40

Key Financial Figures

  • $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 29, 2024 Palisade Bio, Inc. By: /s/ J.D. Finley J.D. Finley Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.